The coronavirus (COVID-19) pandemic has affected investment plans of Russian businesses of different segments rather similarly. The largest share of companies had to revise their investment plans and decrease investment in some segments, while increasing it in others.

It is expected that in 2020, all branches of the Polish economy will record a negative level of investment due to the coronavirus pandemic. The most significant drop in investments will affect accommodation and catering, and the wholesale trade sector will be least affected..

For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

The coronavirus (SARS-CoV-2) outbreak, dubbed COVID-19, is first and foremost a human tragedy, affecting millions of people globally. The contagious coronavirus, which broke out at the close of 2019, has led to a medical emergency across the world, with the World Health Organization officially declaring the novel coronavirus a pandemic on March 11, 2020. Read More

In a survey among U.S. companies operating in China conducted in June 2022, about 17 percent of respondents stated that due to China's COVID-19 control measures, the estimated value of paused, delayed, or canceled investment plans exceeded 50 million U.S. dollars. 27 percent of surveyed U.S. companies said that their investment value affected by COVID-19 was between 10 and 25 million U.S. dollars.

The Coronavirus (SARS-CoV-2) outbreak, dubbed COVID-19, is first and foremost a human tragedy, affecting millions of people globally. The contagious Coronavirus, which broke out at the close of 2019, has led to a medical emergency across the world, with the World Health Organization officially declaring the novel Coronavirus a pandemic on March 11, 2020. Read More

The Coronavirus (SARS-CoV-2) outbreak, dubbed COVID-19, is first and foremost a human tragedy, affecting millions of people globally. The contagious Coronavirus, which broke out at the close of 2019, has led to a medical emergency across the world, with the World Health Organization officially declaring the novel Coronavirus a pandemic on March 11, 2020. Read More

The Covid19 Investment Line of Guarantees has mobilized financing for companies in all sectors of activity. The sectoral distribution data show that the companies in the sectors most affected by COVID-19 have received the most guaranteed financing, which has enabled them to cover their liquidity needs and maintain their activity. This file shows the closing data of the Covid19 Guarantee line, Investment modality, by sector of activity. It provides information on the number of operations, the number of companies that have requested guarantees, the amount of the guarantee requested and the total amount of financing that these guarantees have made possible, broken down by the different sectors of activity.

The Coronavirus (SARS-CoV-2) outbreak, dubbed COVID-19, is first and foremost a human tragedy, affecting millions of people globally. The contagious Coronavirus, which broke out at the close of 2019, has led to a medical emergency across the world, with the World Health Organization officially declaring the novel Coronavirus a pandemic on March 11, 2020. Read More

Investment cannot be separated from the level of return and risk inherent in assets. Today, investment instruments are not only stocks, currencies, bonds, deposits, savings and others. The beginning of Bitcoin’s emergence as a pioneer of Cryptocurrency was in 2009. Crypto assets are emerging rapidly and are accompanied by an increase in the number of transactions each period. The growth in the market capitalization value of crypto assets has also grown significantly. During COVID-19, many investments, such as stocks, experienced a decline due to market uncertainty. The results of this study prove that with the existence of COVID-19, the crypto market is not affected. Crypto is an attraction characterized by a high degree of fluctuation, and there is no limit to transactions in the open market 24 hours to trade. The Cryptocurrency market is currently a market that can provide short-term benefits to risk-taking investors, while the market in other investment instruments is declining. 78% of the value capitalization of the top 200 cryptocurrencies is represented by the top 9 cryptos used as samples in this study. So that if there is a decrease in these 9 cryptos, it will also have an impact on the overall capitalization value of crypto in the market. The future development of Cryptocurrencies will no longer be digital assets traded with many speculators who can control prices, it can even be digital money that can be used worldwide without any transaction fees and is controlled on a blockchain system. (2023-01-12)

In 2020, the global economy was brought to a standstill because of the coronavirus (COVID-19) pandemic. Foreign investment into commercial real estate in the United States was also affected, with 44 percent of National Association of Realtors (NAR) members reporting that travel bans having impacted their international business. Additionally, approximately 22 percent of respondents claimed that the pandemic impacted the availability of credit and lenders. The impacts of the pandemic continued to obstruct cross-border investments throughout 2021: Approximately 25 percent of respondents complained about travel bans and 14 percent - about social distancing affecting their work.

The Coronavirus (SARS-CoV-2) outbreak, dubbed COVID-19, is first and foremost a human tragedy, affecting millions of people globally. The contagious Coronavirus, which broke out at the close of 2019, has led to a medical emergency across the world, with the World Health Organization officially declaring the novel Coronavirus a pandemic on March 11, 2020. Read More

The Coronavirus (SARS-CoV-2) outbreak, dubbed COVID-19, is first and foremost a human tragedy, affecting millions of people globally. The contagious coronavirus, which broke out at the close of 2019, has led to a medical emergency across the world, with the World Health Organization officially declaring the novel coronavirus a pandemic on March 11, 2020.

The outbreak of coronavirus (COVID-19) changed the agenda of many Italian companies in 2020. The results of a survey conducted in March 2020 revealed that 49 percent of companies will cut off their advertising and media spending, while 45 percent of them will reduce the investments in marketing activities. Business development was the third-most hit category of investments affected by a significant decline: 39 percent of Italian businesses is planning to reduce spending on that area.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Fact and Figures page.

The COVID-19 vaccine market, while experiencing a significant surge during the initial pandemic years, is now facing a period of contraction. The market's rapid expansion was driven by urgent global health needs, mass vaccination campaigns, and substantial government investment. However, the deceleration of the CAGR to -37.4% reflects a shift towards a more stable, albeit smaller, market. This downturn is attributable to several factors. Firstly, a large portion of the global population has already received primary vaccination courses, reducing immediate demand. Secondly, the emergence of new variants and the waning efficacy of initial vaccines have led to booster campaigns, but these are less extensive than the initial rollout. Furthermore, ongoing efforts towards developing next-generation vaccines, including those targeting newer variants or offering broader protection, are influencing the market landscape. The market segmentation by type (mRNA, viral vector, etc.) and application (primary vaccination, booster doses) will continue to be crucial factors influencing the market's evolution, with ongoing research and development likely driving future growth in specific segments. The competitive landscape remains highly consolidated with major players like Pfizer, Moderna, Johnson & Johnson, and others holding significant market share. These companies are actively engaged in expanding their vaccine portfolios, securing supply agreements, and exploring new market opportunities, particularly in emerging economies and for long-term vaccination programs. The geographical distribution of the market remains regionally diverse. North America and Europe, with their advanced healthcare systems and early adoption of vaccines, historically held the largest market shares. However, as vaccination programs progress in other regions, we can expect a gradual shift in market share distribution towards Asia Pacific and other developing regions as these areas increase vaccination rates and investment in related healthcare infrastructure. The long-term market will be driven by factors such as the emergence of new variants, the development of updated vaccines, the need for booster shots, and the potential for seasonal COVID-19 vaccination programs. Continued government support and private investment will be crucial for ensuring the long-term viability and sustainability of the COVID-19 vaccine market. Given the potential for future pandemics, the market is likely to remain relevant though significantly reduced compared to its peak during the initial pandemic phases.

Nucleic Acid Extraction Instrument (COVID-19) Market Outlook

The global Nucleic Acid Extraction Instrument market, driven significantly by the COVID-19 pandemic, is anticipated to show robust growth from 2024 to 2032, with an expected CAGR of approximately 8.4%. The surge in demand for these instruments is primarily attributed to the increased necessity for accurate and rapid diagnostic testing during health crises such as the COVID-19 pandemic.

The COVID-19 pandemic has underscored the importance of effective diagnostic tools, profoundly affecting the Nucleic Acid Extraction Instrument market. As the virus spread globally, the need for efficient and rapid testing became paramount, propelling the adoption of nucleic acid extraction technologies. These instruments are critical in isolating and purifying nucleic acids from samples, a crucial step in detecting viral infections, including SARS-CoV-2. This urgent need drove substantial investments and innovations in the field, further fueling market growth.

Another significant growth factor for this market is the ongoing advancements in biotechnology and molecular diagnostics. The continuous development of automated and semi-automated nucleic acid extraction instruments has enhanced the efficiency and accuracy of diagnostic processes. These advancements not only reduce manual errors but also increase throughput, making them highly desirable in clinical settings. The integration of advanced software and robotics in these instruments has further streamlined the extraction process, leading to higher adoption rates across various end-users.

Moreover, the increasing prevalence of infectious diseases and the rising awareness about early disease detection are crucial drivers of market growth. Governments and healthcare organizations worldwide are investing heavily in diagnostic infrastructure to improve public health responses to outbreaks. This has led to a greater emphasis on robust testing frameworks, where nucleic acid extraction instruments play a pivotal role. Additionally, the expansion of research activities in genomics and personalized medicine has further augmented the demand for these instruments, as they are essential tools in genetic and clinical research.

The role of Nucleic Acid Extractors has become increasingly significant in the context of modern diagnostics and research. These devices are pivotal in the extraction of nucleic acids, which are essential for a wide range of applications, from clinical diagnostics to forensic investigations. The efficiency and precision offered by these extractors have made them indispensable tools in laboratories worldwide. As the demand for rapid and accurate testing continues to grow, the development and deployment of advanced nucleic acid extractors are expected to accelerate, further driving market growth. Their integration into diagnostic workflows not only enhances the speed of testing but also improves the reliability of results, which is crucial in managing public health challenges.

Regionally, North America holds a substantial share of the nucleic acid extraction instrument market, driven by robust healthcare infrastructure, significant investment in research and development, and early adoption of advanced diagnostic technologies. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, attributable to the increasing healthcare expenditure, growing awareness about diagnostic technologies, and rising prevalence of infectious diseases. Countries like China and India are making significant strides in healthcare advancements, which bodes well for market expansion in this region.

Product Type Analysis

In the nucleic acid extraction instrument market, product type segmentation includes automated, semi-automated, and manual instruments. Automated instruments are witnessing significant demand due to their efficiency, speed, and accuracy. These systems are designed to handle high-throughput processing, making them ideal for large laboratories and diagnostic centers. The automation reduces the manual intervention required, thereby minimizing errors and ensuring consistent results. The growing trend of laboratory automation and the adoption of next-generation sequencing (NGS) technologies are further propelling the demand for automated nucleic acid extraction instruments.

Semi-automated instruments are also gaining traction, particularly in medium-sized labora

Covid-19 Rapid Test Kits Market Outlook

The Covid-19 Rapid Test Kits market size was valued at USD 5.3 billion in 2023 and is projected to reach USD 12.8 billion by 2032, growing at a CAGR of 10.1% over the forecast period. The rapid growth of this market is primarily driven by the ongoing need for quick and efficient testing solutions to manage and mitigate the spread of the Covid-19 virus. The global demand for these tests has surged due to continuous waves of infections, emerging variants, and the need for widespread testing in both public health and private sectors.

One of the primary growth factors for the Covid-19 Rapid Test Kits market is the persistent and evolving nature of the pandemic. Despite the development and distribution of vaccines, new variants of the virus have emerged, necessitating ongoing testing to monitor and control outbreaks. Rapid test kits offer a convenient and efficient method for identifying infections quickly, allowing for timely isolation and treatment of affected individuals. The ease of use and quick turnaround time of these kits make them invaluable tools in the fight against Covid-19, driving their widespread adoption across various sectors.

Another significant growth driver is the continuous advancements in testing technologies. Companies and research institutions have been investing heavily in the development of more accurate, reliable, and user-friendly rapid test kits. Innovations such as improved sensitivity and specificity, reduced time to result, and the ability to detect multiple variants of the virus are enhancing the effectiveness of these tests. This ongoing innovation is expected to sustain the demand for rapid test kits, even as vaccination efforts progress and other public health measures are implemented.

The expansion of testing infrastructure and increased accessibility are also crucial factors contributing to the market's growth. Governments and healthcare organizations worldwide have been ramping up their testing capacities by establishing new testing centers and increasing the availability of rapid test kits. Initiatives to provide free or subsidized testing, especially in hard-hit and underserved areas, have further boosted the demand for these kits. Additionally, the approval of at-home test kits has empowered individuals to conduct tests conveniently, further driving market growth.

The introduction of RDT (Rapid Diagnostic Test) COVID-19 Test Kit has revolutionized the way testing is conducted, providing a quick and efficient solution to detect the presence of the virus. These kits are designed to deliver results within minutes, making them an essential tool in both clinical and non-clinical settings. The convenience offered by RDT kits has facilitated mass testing efforts, particularly in areas with limited access to laboratory facilities. Their ease of use allows for widespread deployment, enabling healthcare providers to swiftly identify and isolate infected individuals, thereby curbing the spread of the virus. As the pandemic evolves, the role of RDT kits in ensuring timely and accurate testing remains critical, supporting public health initiatives globally.

From a regional perspective, North America and Europe have been leading the market for Covid-19 Rapid Test Kits due to their robust healthcare infrastructure, significant investment in testing capabilities, and proactive government policies. However, the Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by large population bases, increasing healthcare expenditure, and rising awareness about the importance of testing. Emerging economies in Latin America and the Middle East & Africa are also anticipated to contribute significantly to market growth, as they continue to enhance their testing capacities and healthcare infrastructure.

Product Type Analysis

The Covid-19 Rapid Test Kits market by product type is segmented into Antigen Test Kits, Antibody Test Kits, and PCR Test Kits. Each of these product types plays a critical role in the detection and management of Covid-19 infections, catering to different testing needs and scenarios. Antigen test kits are designed to detect specific proteins from the virus, offering quick results and being widely used in mass screening and point-of-care settings. These kits are part

According to data provided by the Institute for Mergers, Acquisitions and Alliances (IMAA) in a survey of private equity investors and professionals in the DACH region, the industry that will be most negatively hit by the COVID-19 virus will be the vehicle construction and accessories sector. 91 percent of respondents indicated that this industry would see negative ramifications due to the pandemic.

COVID-19 affected the world’s economy severely and increased the inflation rate in both developed and developing countries. COVID-19 also affected the financial markets and crypto markets significantly, however, some crypto markets flourished and touched their peak during the pandemic era. This study performs an analysis of the impact of COVID-19 on public opinion and sentiments regarding the financial markets and crypto markets. It conducts sentiment analysis on tweets related to financial markets and crypto markets posted during COVID-19 peak days. Using sentiment analysis, it investigates the people’s sentiments regarding investment in these markets during COVID-19. In addition, damage analysis in terms of market value is also carried out along with the worse time for financial and crypto markets. For analysis, the data is extracted from Twitter using the SNSscraper library. This study proposes a hybrid model called CNN-LSTM (convolutional neural network-long short-term memory model) for sentiment classification. CNN-LSTM outperforms with 0.89, and 0.92 F1 Scores for crypto and financial markets, respectively. Moreover, topic extraction from the tweets is also performed along with the sentiments related to each topic.

Oral Covid-19 Drug Market Outlook

The global market size for oral Covid-19 drugs in 2023 was valued at approximately USD 6.8 billion, and it is forecasted to reach USD 15.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.8%. The increasing prevalence of Covid-19 variants and the continuous efforts to develop effective treatment options are primary drivers of this market's growth.

One of the major growth factors for the oral Covid-19 drug market is the ongoing mutation of the virus. The emergence of new variants has underscored the necessity for versatile and accessible treatment options. Oral drugs provide a straightforward and non-invasive method of administration, which can be easily scaled and distributed. This makes them particularly valuable in combating the virus in both developed and developing regions. Moreover, as the pandemic continues to affect global health systems, there is a sustained demand for effective treatments that can alleviate the burden on hospitals and healthcare facilities.

Another significant driver is the rising investment in pharmaceutical research and development. Governments, private sectors, and international organizations are funnelling substantial funds into the development of effective oral treatments for Covid-19. This influx of capital has accelerated the pace at which new drugs are being developed, tested, and brought to market. Furthermore, advancements in biotechnology and drug delivery systems have enabled the creation of more efficient and targeted therapeutics, enhancing the efficacy of oral Covid-19 drugs.

The market is also propelled by the increasing acceptance and adoption of oral treatments over intravenous options. Oral drugs are more convenient for patients, as they can be self-administered with ease. This reduces the need for hospital visits and lowers the risk of hospital-acquired infections. Additionally, oral medications typically have fewer side effects compared to their intravenous counterparts, making them a more attractive option for long-term use in managing Covid-19 symptoms and preventing severe cases.

Regionally, North America holds a significant share of the global oral Covid-19 drug market, driven by high healthcare spending, advanced medical infrastructure, and a robust pharmaceutical sector. However, the Asia Pacific region is expected to see the fastest growth, owing to its large population, increasing healthcare access, and the growing incidence of Covid-19 cases. Additional factors such as government support and regional collaborations further bolster market expansion in this area.

Drug Type Analysis

The oral Covid-19 drug market can be segmented by drug type into antiviral drugs, immunomodulators, and others. Antiviral drugs form the cornerstone of this market segment, as they are specifically designed to target and inhibit the replication of the virus. These drugs have been instrumental in reducing the severity and duration of Covid-19 symptoms. The demand for antiviral drugs is expected to remain high as they are continually refined to combat new viral strains effectively. Pharmaceutical companies are investing heavily in the development and clinical trials of new antiviral agents, aiming to improve efficacy and reduce side effects.

Immunomodulators constitute another critical segment within the oral Covid-19 drug market. These drugs work by modulating the body's immune response to the virus, thereby preventing the overactive immune responses that lead to severe complications such as cytokine storms. Immunomodulators are particularly beneficial for patients with underlying health conditions that compromise their immune systems. The growing understanding of the immune mechanisms involved in Covid-19 has accelerated the development of targeted immunomodulatory therapies, contributing to the expansion of this market segment.

Other drug types in this market segment include a variety of therapeutic agents that do not fall strictly into the categories of antivirals or immunomodulators. These might include supportive care medications, symptom-specific treatments, and novel therapeutic approaches under investigation. While this segment is smaller compared to antivirals and immunomodulators, it remains important due to the diverse needs of Covid-19 patients. The continuous innovation in drug discovery processes ensures that new and effective drugs are regularly introduced into this category.

The competition within each drug type segment is intense, with numerous pharmaceutical companies vy

Remdesivir COVID-19 Sales Market Outlook

The global Remdesivir COVID-19 sales market is witnessing robust growth, with the market size estimated to reach approximately USD 3.5 billion by 2023. It is projected to reach USD 5.8 billion by 2032, reflecting a Compound Annual Growth Rate (CAGR) of 5.8% from 2024 to 2032. This upsurge is predominantly driven by the continuous demand for effective COVID-19 treatment options, the ongoing impact of the pandemic on public health, and the increasing accessibility of antiviral medications across various regions. The pandemic's persistence and the emergence of new virus variants have further cemented the role of Remdesivir as a critical therapeutic option in the management of COVID-19 infections.

One of the key growth factors fueling the Remdesivir market is its approval and endorsement by major health regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These endorsements have significantly bolstered the credibility and adoption rate of Remdesivir worldwide. As countries continue to grapple with the pandemic, the urgency to equip healthcare systems with effective antiviral drugs like Remdesivir has intensified. Moreover, the increasing investment in healthcare infrastructure and the strategic stockpiling of antiviral medications by governments have significantly contributed to the market's expansion. The ongoing research and development efforts to improve the drug's efficacy and safety profile are expected to further enhance its market penetration.

Another significant driver for the market is the strategic collaborations and partnerships between pharmaceutical companies and healthcare providers. These collaborations aim to ensure the uninterrupted supply of Remdesivir, thereby addressing the fluctuating demand during different waves of the pandemic. Additionally, the growing awareness about the benefits of early antiviral intervention in COVID-19 treatment has led to an increase in its prescription rate. Healthcare providers are increasingly recommending Remdesivir as part of comprehensive COVID-19 treatment regimens, thereby augmenting its sales. The pharmaceutical industry continues to innovate in areas such as dosage optimization and combination therapies, further boosting the market's potential.

The rising incidence of COVID-19 cases globally, coupled with the threat of emerging variants, has prompted healthcare systems to maintain robust treatment arsenals. Remdesivir, being one of the few antiviral drugs with proven efficacy in treating COVID-19, remains a preferred choice among healthcare professionals. The market is also benefiting from the increasing acceptance of antiviral treatments among patients, driven by positive clinical outcomes. Furthermore, the focus on improving patient outcomes through evidence-based treatment protocols has led to a consistent demand for Remdesivir, thereby sustaining its sales momentum. The ongoing vaccination efforts, although significant, have not diminished the need for effective antiviral therapies, especially in high-risk populations.

Regionally, North America holds a prominent position in the Remdesivir COVID-19 sales market, attributed to strong healthcare infrastructure, high awareness levels among healthcare professionals, and significant government support. The Asia Pacific region, however, is expected to exhibit the highest growth rate during the forecast period, driven by increasing healthcare expenditures and the rising burden of COVID-19 cases. Europe remains a key market with substantial demand from countries severely affected by the pandemic. Latin America and the Middle East & Africa are anticipated to show moderate growth, with ongoing efforts to improve healthcare access and distribution networks playing a crucial role in driving demand.

Dosage Form Analysis

The dosage form segment of the Remdesivir market is primarily bifurcated into injectable and oral forms. As of now, the injectable form of Remdesivir dominates the market, given its proven efficacy in delivering the medication directly into the bloodstream, ensuring rapid action against the virus. Hospitals and healthcare settings prefer this form due to its quick onset of action, especially in severe COVID-19 cases. The injectable form's dominance is further bolstered by clinical guidelines and treatment protocols that prioritize its use for hospitalized patients. Pharmaceutical companies are focusing on enhancing production capabilities to meet the rising demand for injectables, especially in regions with high infection rates.